News
4d
MedPage Today on MSNBone Health in Duchenne Muscular DystrophyAn alternative to using standard glucocorticoids is the synthetic dissociative steroid vamorolone (Agamree), which was ...
A cell therapy preserves muscle structure and function in laboratory mice with a type of disease similar to Duchenne muscular ...
K.S.R.A. Praneeth, an 18-year-old battling Duchenne Muscular Dystrophy, competed in the World IPCA Chess Championship in Goa, ...
A 12-year-old boy from Carthage, Tennessee finds joy in his power wheelchair. His family are hoping for a cure for his muscular disease, Duchenne.
First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple ...
Cumberland Pharmaceuticals Inc (CPIX) reports a 10% revenue increase and strategic international expansions, despite facing ...
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the ...
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...
6d
Amazon S3 on MSNThe story of Sarepta's Duchenne gene therapyThe last couple of weeks has been particularly distressing for Duchenne muscular dystrophy patients and their families. The ...
Cumberland Pharmaceuticals' Q2 2025 earnings highlight revenue growth, clinical progress in ifetroban for DMD, and Vibativ's global expansion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results